SeraCare Life Sciences, a manufacturer of life sciences tools, bulk plasma, and quality controls for diagnostic companies and clinical laboratories, announced an expansion of its research and manufacturing facilities at its Milford, Massachusetts headquarters. The addition of the state-of-the-art facility was driven by new companion diagnostic manufacturing opportunities with key diagnostic partners and enhances the company's ability to manufacture innovative molecular diagnostic kits and components used in in vitro diagnostics and companion diagnostics under stringent design control and quality systems.
"The expansion of our research and manufacturing capabilities is an important element in our overall growth strategy for SeraCare," said Charlie Mamrak, CEO of SeraCare. "Over the past year, we have made a number of significant investments including the recent acquisition of KPL, a leader in immunoassay reagents, and implementation of SAP enterprise resource planning software. These investments position SeraCare for continued growth in both our existing customer base as well as emerging markets such as molecular and companion diagnostics."
Under this initiative, SeraCare is adding five thousand square feet of space to its Milford research and manufacturing building. This state-of-the-art facility will include an ISO 8 classified clean room, four advanced molecular laboratories and a sophisticated air handling and purifying system. The new laboratories will also feature polymerase chain reaction (PCR) capabilities, amplicon segregation process design and sequencing instrumentation to aid in the development of molecular diagnostic kits and components.
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis